**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 87473

**Manuscript Type:** ORIGINAL ARTICLE

***Observational Study***

**Knowledge, attitude, and practice of patients living with inflammatory bowel disease: A cross-sectional study**

Shao XX *et al*. KAP of IBD among patients

Xiao-Xiao Shao, Lu-Yan Fang, Xu-Ri Guo, Wei-Zhong Wang, Rui-Xin Shi, Dao-Po Lin

**Xiao-Xiao Shao, Lu-Yan Fang, Xu-Ri Guo, Dao-Po Lin,** Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang Province, China

**Wei-Zhong Wang, Rui-Xin Shi,** The Second Clinical Medical College, Wenzhou Medical University, Wenzhou 325035, Zhejiang Province, China

**Author contributions:** Fang LY and Guo XR carried out the study and participated in collecting data; Shao XX drafted the manuscript; Wang WZ and Shi RX performed the statistical analysis and participated in its design; Lin DP participated in the acquisition, analysis, and interpretation of data; and all authors read and approved the final manuscript.

**Supported by** Wenzhou Science and Technology Bureau, No. Y20220031.

**Corresponding author: Dao-Po Lin, MD,** Department of Gastroenterology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, No. 109 Xueyuan Western Road, Wenzhou 325027, Zhejiang Province, China. wmuldp@163.com

**Received:** August 14, 2023

**Revised:** October 20, 2023

**Accepted:** November 14, 2023

**Published online:**

**Abstract**

BACKGROUND

Patients with inflammatory bowel diseases (IBDs) generally have poor knowledge, attitude, and practice of their disease, while the data from China are lacking.

AIM

To address this knowledge disparity among Chinese patients with IBD.

METHODS

This web-based, cross-sectional study was conducted on a cohort of IBD patients who visited the Second Affiliated Hospital of Wenzhou Medical University between December 2022 and February 2023. Their socio-demographic information and the knowledge, attitude, and practice scores were collected and estimated using a self-designed questionnaire. Pearson’s correlation analysis was used to determine the pairwise correlations among knowledge, attitude, and practice scores. A multivariate logistic regression analysis was further performed to determine the independent factors associated with their knowledge, attitude, and practice scores.

RESULTS

A total of 353 patients (224 males) with IBD completed the questionnaires. The mean knowledge, attitude, and practice scores were 10.05 ± 3.46 (possible range: 0-14), 41.58 ± 5.23 (possible range: 0-56), 44.20 ± 7.39 (possible range: 0-56), respectively, indicating good knowledge, positive attitude, and proactive practice toward IBD. Pearson’s correlation analysis showed that the knowledge score had significant positive correlations with the attitude score (*r* = 0.371, *P* < 0.001) and practice score (*r* = 0.100, *P* < 0.001). The attitude score had a significant positive correlation with the practice score (*r* = 0.452, *P* < 0.001). Moreover, multivariate logistic regression analysis showed that aged 30-40 years [odds ratio (OR) = 4.06, 95% confidence interval (CI): 1.04-15.82, *P* = 0.043], middle school education (OR = 3.98, 95%CI: 1.29-12.33, *P* = 0.017), high school/technical secondary school education (OR = 14.06, 95%CI: 3.92-50.38, *P* < 0.001), and junior college/bachelor’s degree and above education (OR = 15.20, 95%CI: 4.15-55.650, *P* < 0.001) were independently associated with good knowledge. The higher knowledge score was independently associated with a positive attitude (OR = 1.23, 95%CI: 1.11-1.36, *P* < 0.001). The higher attitude score was independently associated with proactive practice (OR = 1.20, 95%CI: 1.11-1.30, *P* < 0.001).

CONCLUSION

Chinese patients with IBD might have good knowledge, a positive attitude, and proactive practice toward their disease. However, a small number of specific items require education.

**Key Words:** Attitude; Cross-sectional study; Inflammatory bowel disease; Knowledge; Practice; Questionnaire

Shao XX, Fang LY, Guo XR, Wang WZ, Shi RX, Lin DP. Knowledge, attitude, and practice of patients living with inflammatory bowel disease: A cross-sectional study. *World J Gastroenterol* 2023; In press

**Core Tip:** To address this knowledge disparity among Chinese patients with inflammatory bowel disease (IBD), a web-based, cross-sectional study was conducted on 353 IBD patients (224 males). Their mean knowledge, attitude, and practice scores were 10.05 ± 3.46 (range: 0-14), 41.58 ± 5.23 (range: 0-56), and 44.20 ± 7.39 (range: 0-56), respectively. Multivariate logistic regression analysis showed that age and education were independently associated with knowledge. Knowledge was independently associated with attitude. The attitude was independently associated with the practice. In conclusion, patients with IBD in China might have good knowledge, a positive attitude, and proactive practice toward their disease. However, some specific items require education.

**INTRODUCTION**

Inflammatory bowel disease (IBD) is a chronic, non-specific inflammation of the gastrointestinal tract, including ulcerative colitis and Crohn’s disease. The IBD usually develops before age 30[1-3]. Moreover, IBD is associated with a poor quality of life and may increase colorectal cancer risk[2-4]. The individual management strategy of IBD is tailored to each patient according to diagnosis, disease activity grade, disease lesion, and personal prognostic factors[1,3-7]. Despite this, IBD continues to be difficult to manage, as treatment adverse effects and repeated exacerbation/recurrence episodes can eventually necessitate costly second-line therapies or even surgery[8-11].

Maintaining proper lifestyle habits is necessary and complementary to medical treatments in patients with IBD[12,13]. Fundamental to patient self-management is knowing which foods and situations to avoid and what can be done to alleviate symptoms[12,13]. To implement adequate self-management, a thorough understanding of IBD causes, risk factors for exacerbation/recurrence, disease mechanisms, and treatments is essential, and this knowledge needs to be translated into more effective (but not infallible) self-management. In addition, since there is no cure for IBD, self-management is essential to its treatment[1,5,14]. Indeed, since the management of IBD necessitates the adoption of healthy lifestyle habits, IBD patients are the first to be accountable for their health[12,13], which requires proper knowledge, attitudes, and practice (KAP) of the specific lifestyle routines to implement. The appropriate KAP about IBD can reduce medical acceleration in patients with IBD[15]. Since the 1990s, however, some studies have revealed that patients with IBD have misconceptions and limited knowledge of their disease[16-21]. Such studies are important to identify the gaps in knowledge that represent barriers to the proper management of IBD. Identifying these obstacles could also aid in designing interventions to enhance or rectify knowledge[22,23]. Owing to significant differences in culture, economy, health literacy, healthcare systems, and government policies, KAP data are usually very specific to a given population. Of note, data about the KAP toward IBD in Chinese patients with IBD are lacking.

The KAP methodology provides quantitative and qualitative data on the misconceptions that could represent obstacles to a specific task/subject in a specific population[22,23]. Hence, this study aimed to investigate the KAP of patients with IBD toward their disease in Zhejiang Province, China. The results could help healthcare providers to improve the patient’s self-management of IBD.

**MATERIALS AND METHODS**

***Study design and participants***

It was a cross-sectional study conducted on patients with IBD at the Second Affiliated Hospital of Wenzhou Medical University using convenience sampling. Our study was approved by the ethics committee of the same hospital (approval No. 2022-K-184-02). Each patient provided written informed consent before completing the survey.

***Procedures***

The questionnaire was designed with reference to the World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010[24] and the clinical nutrition guideline for IBD by the European Society for Clinical Nutrition and Metabolism in 2016[25]. Then, the questionnaire was submitted to 5 experts for review. After the modifications based on their comments, a small-scale validation was performed (33 copies), showing a Cronbach’s α of 0.854.

The final questionnaire was in Chinese patients with IBD and included four dimensions with 62 items. Among them, the socio-demographic information dimension consisted of 20 items. The knowledge, attitude, and practice dimensions consisted of 14 items each. The items in the knowledge dimension were scored 1 point for a correct answer and 0 points for a wrong or unclear answer (total score of 0-14). The options from positive to negative (*e.g.,* 4 to 0) were assigned for the attitude and practice dimension. The total scores were 0-56 for the attitude dimension and 0-56 for the practice dimension. The threshold for good knowledge, positive attitude, and proactive practice was ≥ 70.0%.

The questionnaires were administered to the participants through WeChat on the SoJump platform (https://www.wjx.cn/app/survey.aspx). A given IP address could be used to submit a questionnaire only once. All items must be answered before the submission of the questionnaire. Questionnaires that took less than 2 min to complete or with obvious filling patterns were excluded.

***Statistics analysis***

All analyses were performed using Stata 17.0 (Stata Corporation, College Station, TX, United States). The normal distribution of continuous data was checked using the Kolmogorov-Smirnov test. Those continuous data conforming to the normal distribution were presented as means ± SD and analyzed using Student’s *t*-test (two groups) or ANOVA (more than two groups). Otherwise, they were presented as medians (ranges) and analyzed using the Wilcoxon-Mann-Whitney *U*-test (two groups) or the Kruskal-Wallis analysis of variance (more than two groups). Categorical data were displayed as numbers (percent). Pearson’s correlation analysis was used to determine the pairwise correlations among KAP scores. A multivariate logistic regression analysis was performed to determine the independent factors relevant to the KAP score. Variables with *P*-values less than 0.20 in the univariate analysis were included in the multivariate logistic analysis. Two-sided *P*-values below 0.05 were regarded as statistically significant.

**RESULTS**

The present study included a total of 353 valid questionnaires. Most of the participants were male (63.5%), aged 20-30 (32.9%) years. The other social-demographic data are presented in Table 1. The mean knowledge, attitude, and practice scores were 10.05 ± 3.46 (possible range: 0-14), 41.58 ± 5.23(possible range: 0-56), and 44.20 ± 7.39 (possible range: 0-56), respectively, indicating good knowledge, positive attitude, and proactive practice toward IBD (Table 1).

The knowledge items with the lowest score were K2 (21.0%, “At present, and many factors such as heredity, immunity, environment, and microorganisms are involved in the pathogenesis of the disease”), K11 (42.2%, “There are no side effects under the therapy of glucocorticoids, *etc.*”), K4 (60.1%, “Extraintestinal manifestations of IBD include oral ulcers, joint injury, skin injury, eye lesions, hepatobiliary diseases, *etc.*”), and K13 (65.7%, “All patients with IBD cannot normally absorb the nutrients they intake”) (Table 2). The attitude item with the lowest score was A8 (“I think that treatment can be stopped when the colonoscopy shows mucosal healing *i.e.,* complete healing of colonic erosions and ulcers”) (Table 3). The practice item with the lowest score was P11 (“I will use a diet diary to identify foods that may cause discomforts such as abdominal pain or diarrhea and try to avoid them in my future diet”). In addition, 98.0% of the participants were willing to stop smoking and drinking (Table 4).

The knowledge score was found to be related to the attitude score (*r* = 0.371, *P* < 0.001) and practice (*r* = 0.100, *P* < 0.001) score, respectively. The attitude score was related to the practice score (*r* = 0.452, *P* < 0.001) (Table 5). Moreover, multivariate logistic regression analysis suggested that aged 30-40 years [odds ratio (OR) = 4.06, 95% confidence interval (CI): 1.04-15.82, *P* = 0.043], middle school education (OR = 3.98, 95%CI: 1.29-12.33, *P* = 0.017), high school/technical secondary school education (OR = 14.06, 95%CI: 3.92-50.38, *P* < 0.001), and junior college/bachelor’s degree and above education (OR = 15.20, 95%CI: 4.15-55.650, *P* < 0.001) were independently linked with the knowledge score (Table 6). The knowledge score (OR = 1.23, 95%CI: 1.11-1.36, *P* < 0.001) was independently associated with the attitude score (Table 7). In addition, the attitude score (OR = 1.20, 95%CI: 1.11-1.30, *P* < 0.001) had an independent effect on the practice score (Table 8).

**DISCUSSION**

The findings of our study suggested that Chinese patients with IBD had good knowledge, positive attitudes, and proactive practice toward their disease. Nevertheless, some specific items warranting more education were identified. These outcomes may be useful for the management and self-management of IBD patients in clinical practice.

Several studies revealed misconceptions and relatively poor knowledge in patients with IBD about their disease[16-21]. A study from England published 30 years ago already acknowledged that patients with IBD had poor knowledge regarding their disease but were willing to acquire information[16]. More contemporary data indicated little progress since then, *i.e.,* that the knowledge of patients with IBD toward their disease was poor[17-21], including in New Zealand[17], Canada[18], Israel[19], Poland[20], and South Korea[21]. Surprisingly, in the present study, the patients with IBD showed good KAP toward IBD, but it could be noted that most participants had a junior college/bachelor’s degree and above education and were receiving expensive biological agents, thereby suggesting a higher socioeconomic status that could influence the results.

The present investigation also demonstrated that age and educational attainment were independently associated with knowledge scores. Specific knowledge items that need improvement include the etiology of IBDs, the possible extraintestinal manifestations of IBDs, the side effects of glucocorticoids, and nutrient absorption. Even though the other knowledge items had high scores, none scored above 90%, indicating they would benefit from additional instruction. Furthermore, knowledge was the only factor independently associated with the attitude score, and attitude was the only factor independently connected with the practice score. Hence, improving the knowledge of patient about IBDs should enhance their KAP. Since a proper KAP of IBDs has been associated with better IBD outcomes[15], improving the KAP can improve patient outcomes, given that self-management is at the core of IBD management[12,13].

Still, patients obtain knowledge primarily from available resources (books, the internet, newspapers, *etc.*), their social network, and healthcare professionals. A study highlighted variable access to high-quality information on IBD-related nutrition[26], and nutrition is a major factor influencing the intestinal microflora and the outcomes of IBDs[27-29]. Furthermore, a study in New Zealand showed that the KAP of IBD in the general population was also low[30,31], suggesting that patient education is deficient or ineffective since the patients with IBD have poor KAP. Healthcare providers are the primary source of reliable patient information, but studies unveiled that the KAP of IBD among healthcare providers was also low[32,33]. Having limited knowledge about a disease can impede the spread of accurate information. Therefore, previous studies suggest that priority should be placed on educating patients, healthcare professionals, and the general public.

There are some limitations in this study. It was conducted at a single institution, limiting its applicability to other hospitals in China. The questionnaire was designed by local investigators and was probably influenced by local policies and guidelines, further restricting the exportability of the questionnaire. The study has local scope, and the results cannot be extrapolated to other populations, which makes similar studies necessary in other locations. The study population shows high education and use of biological products, which suggests a selection bias. KAP surveys represent the situation of a specific population at a precise time point. Therefore, studies in other populations and time might be necessary to examine the actual KAP situation in China and the effect of education. Finally, all KAP surveys were susceptible to social desirability bias, in which participants may have been more likely to provide the expected response than the actual answer[34].

**CONCLUSION**

In conclusion, this study suggests that Chinese patients with IBD have good knowledge, positive attitudes, and active practice toward their disease. Nevertheless, some specific items warranting more education were identified, especially regarding the etiology and contributing factors to the disease, extraintestinal manifestations, glucocorticoid side effects, and nutrient absorption.

**ARTICLE HIGHLIGHTS**

***Research background***

The management of inflammatory bowel disease (IBD) necessitates the adoption of healthy lifestyle habits, which requires proper knowledge, attitudes, and practice of the specific lifestyle routines to implement. However, patients with IBD generally have poor knowledge, attitude, and practice (KAP) of their disease, while the data from China are lacking.

***Research motivation***

The motivation of this study is to help healthcare providers to improve the patient’s self-management of IBD.

***Research objectives***

The object of this study is to investigate the KAP of patients with IBD toward their disease in Zhejiang Province, China.

***Research methods***

Self-designed questionnaires were administered to the participants through WeChat on the SoJump platform (https://www.wjx.cn/app/survey.aspx). Pearson’s correlation analysis was used to determine the pairwise correlations among KAP scores. A multivariate logistic regression analysis was further performed to determine the independent factors associated with their KAP scores.

***Research results***

A total of 353 patients (224 males) with IBD completed the questionnaires. Their mean KAP scores were 10.05 ± 3.46 (possible range: 0-14), 41.58 ± 5.23 (possible range: 0-56), 44.20 ± 7.39 (possible range: 0-56), respectively, indicating good knowledge, positive attitude, and proactive practice toward IBD. Age and education were independently associated with their KAP.

***Research conclusions***

Chinese patients with IBD might have good knowledge, a positive attitude, and proactive practice toward their disease. Nevertheless, some specific items warranting more education were identified, especially regarding the etiology and contributing factors to the disease, extraintestinal manifestations, glucocorticoid side effects, and nutrient absorption.

***Research perspectives***

The findings of this study may be useful for the management and self-management of IBD patients in clinical practice.

**REFERENCES**

1 **Rubin DT**, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. *Am J Gastroenterol* 2019; **114**: 384-413 [PMID: 30840605 DOI: 10.14309/ajg.0000000000000152]

2 **Ungaro R**, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. *Lancet* 2017; **389**: 1756-1770 [PMID: 27914657 DOI: 10.1016/S0140-6736(16)32126-2]

3 **Torres J**, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. *Lancet* 2017; **389**: 1741-1755 [PMID: 27914655 DOI: 10.1016/S0140-6736(16)31711-1]

4 **Kalla R**, Ventham NT, Satsangi J, Arnott ID. Crohn's disease. *BMJ* 2014; **349**: g6670 [PMID: 25409896 DOI: 10.1136/bmj.g6670]

5 **Lichtenstein GR**, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. *Am J Gastroenterol* 2018; **113**: 481-517 [PMID: 29610508 DOI: 10.1038/ajg.2018.27]

6 **Terdiman JP**, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT; AGA Institute Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. *Gastroenterology* 2013; **145**: 1459-1463 [PMID: 24267474 DOI: 10.1053/j.gastro.2013.10.047]

7 **Sandborn WJ**. Crohn's disease evaluation and treatment: clinical decision tool. *Gastroenterology* 2014; **147**: 702-705 [PMID: 25046160 DOI: 10.1053/j.gastro.2014.07.022]

8 **Fukuda T**, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. *Intest Res* 2019; **17**: 36-44 [PMID: 30678445 DOI: 10.5217/ir.2018.00126]

9 **Popov J**, Farbod Y, Chauhan U, Kalantar M, Hill L, Armstrong D, Halder S, Marshall JK, Moayyedi P, Kaasalainen S. Patients' Experiences and Challenges in Living with Inflammatory Bowel Disease: A Qualitative Approach. *Clin Exp Gastroenterol* 2021; **14**: 123-131 [PMID: 33953591 DOI: 10.2147/CEG.S303688]

10 **Gravina AG**, Pellegrino R, Zingone F. Editorial: Challenges in Inflammatory Bowel Disease: Current, Future and Unmet Needs. *Front Med (Lausanne)* 2022; **9**: 979535 [PMID: 35924035 DOI: 10.3389/fmed.2022.979535]

11 **Gearry RB**, McCombie AM, Vatn M, Rubin DT, Steinwurz F, Loftus EV, Kruis W, Tysk C, Colombel JF, Ng SC, Van Assche G, Bernstein CN. What Are the Most Challenging Aspects of Inflammatory Bowel Disease? An International Survey of Gastroenterologists Comparing Developed and Developing Countries. *Inflamm Intest Dis* 2021; **6**: 78-86 [PMID: 34124179 DOI: 10.1159/000512310]

12 **Plevinsky JM**, Greenley RN, Fishman LN. Self-management in patients with inflammatory bowel disease: strategies, outcomes, and integration into clinical care. *Clin Exp Gastroenterol* 2016; **9**: 259-267 [PMID: 27601930 DOI: 10.2147/CEG.S106302]

13 **Squires SI**, Boal AJ, Lamont S, Naismith GD. Implementing a self-management strategy in inflammatory bowel disease (IBD): patient perceptions, clinical outcomes and the impact on service. *Frontline Gastroenterol* 2017; **8**: 272-278 [PMID: 29067153 DOI: 10.1136/flgastro-2017-100807]

14 **Ko CW**, Singh S, Feuerstein JD, Falck-Ytter C, Falck-Ytter Y, Cross RK; American Gastroenterological Association Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. *Gastroenterology* 2019; **156**: 748-764 [PMID: 30576644 DOI: 10.1053/j.gastro.2018.12.009]

15 **Park J**, Yoon H, Shin CM, Park YS, Kim N, Lee DH. Higher levels of disease-related knowledge reduce medical acceleration in patients with inflammatory bowel disease. *PLoS One* 2020; **15**: e0233654 [PMID: 32502199 DOI: 10.1371/journal.pone.0233654]

16 **Jones SC**, Gallacher B, Lobo AJ, Axon AT. A patient knowledge questionnaire in inflammatory bowel disease. *J Clin Gastroenterol* 1993; **17**: 21-24 [PMID: 8409293 DOI: 10.1097/00004836-199307000-00007]

17 **Buerkle KS**, Vernon-Roberts A, Ho C, Schultz M, Day AS. A Short Knowledge Assessment Tool Is Valid and Acceptable for Adults with Inflammatory Bowel Disease. *Dig Dis Sci* 2022; **67**: 2049-2058 [PMID: 35511411 DOI: 10.1007/s10620-022-07507-7]

18 **Benchimol EI**, Walters TD, Kaufman M, Frost K, Fiedler K, Chinea Z, Zachos M. Assessment of knowledge in adolescents with inflammatory bowel disease using a novel transition tool. *Inflamm Bowel Dis* 2011; **17**: 1131-1137 [PMID: 21484961 DOI: 10.1002/ibd.21464]

19 **Krauthammer A**, Harel T, Zevit N, Shouval DS, Shamir R, Weiss B. Knowledge of disease and self-management of adolescents with inflammatory bowel diseases. *Acta Paediatr* 2020; **109**: 2119-2124 [PMID: 32026526 DOI: 10.1111/apa.15211]

20 **Breuker G**, Boucher B, Kroon P. On "Supervised exercises compared with radial extracorporeal shock-wave therapy..." Engebretsen K, Grotle M, Bautz-Holter E, et al. Phys Ther. 2011;91:37-47. *Phys Ther* 2011; **91**: 826; author reply 826-826; author reply 827 [PMID: 21531943 DOI: 10.2522/ptj.2011.91.5.826.1]

21 **Kim JY**, Yoon H, Hwang JS, Yang SK, Park SH, Loftus EV Jr. Comparison of Disease-related Knowledge of Patients With Inflammatory Bowel Disease Between the West and the East Using an Updated Questionnaire (IBD-KNOW). *J Clin Gastroenterol* 2020; **54**: 720-724 [PMID: 31764490 DOI: 10.1097/MCG.0000000000001283]

22 **Andrade C**, Menon V, Ameen S, Kumar Praharaj S. Designing and Conducting Knowledge, Attitude, and Practice Surveys in Psychiatry: Practical Guidance. *Indian J Psychol Med* 2020; **42**: 478-481 [PMID: 33414597 DOI: 10.1177/0253717620946111]

23 **Dayrit M**, Taylor A, Yan J, Braichet JM, Zurn P, Taylor A, Shainblum E. WHO code of practice on the international recruitment of health personnel. *Bull World Health Organ* 2008; **86**: 739 [PMID: 18949204 DOI: 10.2471/BLT.08.058578]

24 **Bernstein CN**, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, Gearry R, Goh KL, Hamid S, Khan AG, LeMair AW, Malfertheiner P, Ouyang Q, Rey JF, Sood A, Steinwurz F, Thomsen OO, Thomson A, Watermeyer G. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. *Inflamm Bowel Dis* 2010; **16**: 112-124 [PMID: 19653289 DOI: 10.1002/ibd.21048]

25 **Forbes A**, Escher J, Hébuterne X, Kłęk S, Krznaric Z, Schneider S, Shamir R, Stardelova K, Wierdsma N, Wiskin AE, Bischoff SC. ESPEN guideline: Clinical nutrition in inflammatory bowel disease. *Clin Nutr* 2017; **36**: 321-347 [PMID: 28131521 DOI: 10.1016/j.clnu.2016.12.027]

26 **Prince AC**, Moosa A, Lomer MC, Reidlinger DP, Whelan K. Variable access to quality nutrition information regarding inflammatory bowel disease: a survey of patients and health professionals and objective examination of written information. *Health Expect* 2015; **18**: 2501-2512 [PMID: 24934409 DOI: 10.1111/hex.12219]

27 **Zheng L**, Wen XL. Gut microbiota and inflammatory bowel disease: The current status and perspectives. *World J Clin Cases* 2021; **9**: 321-333 [PMID: 33521100 DOI: 10.12998/wjcc.v9.i2.321]

28 **Qiu P**, Ishimoto T, Fu L, Zhang J, Zhang Z, Liu Y. The Gut Microbiota in Inflammatory Bowel Disease. *Front Cell Infect Microbiol* 2022; **12**: 733992 [PMID: 35273921 DOI: 10.3389/fcimb.2022.733992]

29 **Fernandes D**, Andreyev J. The Role of the Human Gut Microbiome in Inflammatory Bowel Disease and Radiation Enteropathy. *Microorganisms* 2022; **10** [PMID: 36014031 DOI: 10.3390/microorganisms10081613]

30 **Vernon-Roberts A**, Gearry RB, Day AS. The Level of Public Knowledge about Inflammatory Bowel Disease in Christchurch, New Zealand. *Inflamm Intest Dis* 2020; **5**: 205-211 [PMID: 33313073 DOI: 10.1159/000510071]

31 **Groshek J**, Basil M, Guo L, Parker Ward S, Farraye FA, Reich J. Media Consumption and Creation in Attitudes Toward and Knowledge of Inflammatory Bowel Disease: Web-Based Survey. *J Med Internet Res* 2017; **19**: e403 [PMID: 29222081 DOI: 10.2196/jmir.7624]

32 **Umar S**, Kapetanos A. Knowledge, Attitude and Practices of Preventive Health Care Measures in Inflammatory Bowel Disease Patients Among Primary Care Physicians: A Pilot Project. *Am J Gastroenterol* 2017; **112**: S328-S329 [DOI: 10.14309/00000434-201710001-00606]

33 **Benson MJ**, Abelev SV, Corte CJ, Connor SJ, McGregor IS. Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease. *Crohns Colitis 360* 2020; **2**: otaa045 [PMID: 36777304 DOI: 10.1093/crocol/otaa045]

34 **Bergen N**, Labonté R. "Everything Is Perfect, and We Have No Problems": Detecting and Limiting Social Desirability Bias in Qualitative Research. *Qual Health Res* 2020; **30**: 783-792 [PMID: 31830860 DOI: 10.1177/1049732319889354]

**Footnotes**

**Institutional review board statement:** Our study was approved by the ethics committee of the same hospital (Approval No. 2022-K-184-02).

**Informed consent statement:** Each patient provided written informed consent before completing the survey.

**Conflict-of-interest statement:** All the authors report no relevant conflicts of interest for this article.

**Data sharing statement:** No additional data are available.

**STROBE statement:** The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** August 14, 2023

**First decision:** October 8, 2023

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Rodrigues AT, Brazil; Triantafillidis J, Greece **S-Editor:** Wang JJ **L-Editor:** A **P-Editor:** Wang JJ

**Table 1 Characteristics of the participants**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** | ***n* (%)** | **Knowledge** | | **Attitude** | | **Practice** | |
| **mean ± SD** | ***P* value** | **mean ± SD** | ***P* value** | **mean ± SD** | ***P* value** |
| Total | 353 | 10.05 ± 3.46 |  | 41.58 ± 5.23 |  | 44.20 ± 7.39 |  |
| Gender |  |  | 0.468 |  | 0.830 |  | 0.077 |
| Male | 224 (63.5) | 9.95 ± 3.57 |  | 41.62 ± 5.02 |  | 44.72 ± 7.35 |  |
| Female | 129 (36.5) | 10.2 ± 3.28 |  | 41.50 ± 5.59 |  | 43.28 ± 7.40 |  |
| Age, yr (10 cases missing) |  |  | < 0.001 |  | 0.142 |  | 0.886 |
| ≤ 20 | 41 (11.6) | 9.46 ± 3.87 |  | 40.95 ± 5.13 |  | 44.00 ± 8.15 |  |
| 20-30 | 116 (32.9) | 10.87 ± 2.94 |  | 42.41 ± 5.25 |  | 44.37 ± 7.40 |  |
| 30-40 | 85 (24.1) | 10.56 ± 3.03 |  | 41.81 ± 5.24 |  | 43.89 ± 6.92 |  |
| > 40 | 101 (28.6) | 9.02 ± 3.91 |  | 40.88 ± 5.21 |  | 44.70 ± 7.27 |  |
| Ethnicity (1 case missing) |  |  | 0.011 |  | 0.028 |  | 0.609 |
| Han | 341 (96.6) | 10.13 ± 3.39 |  | 41.69 ± 5.16 |  | 44.25 ± 7.41 |  |
| Minorities | 11 (3.1) | 7.45 ± 4.89 |  | 38.18 ± 6.51 |  | 43.09 ± 6.85 |  |
| Residence |  |  | 0.006 |  | 0.059 |  | 0.002 |
| Rural | 149 (42.2) | 9.38 ± 3.72 |  | 44.18 ± 5.19 |  | 43.76 ± 7.76 |  |
| City | 122 (34.6) | 10.66 ± 3.05 |  | 42.48 ± 5.05 |  | 45.97 ± 6.73 |  |
| Suburb/urban-rural combination | 82 (23.2) | 10.35 ± 3.85 |  | 40.95 ± 5.45 |  | 42.35 ± 7.13 |  |
| Education |  |  | < 0.001 |  | 0.003 |  | 0.089 |
| Primary school and below | 25 (7.1) | 6.92 ± 3.53 |  | 40.00 ± 4.97 |  | 42.88 ± 7.21 |  |
| Middle school | 67 (19.0) | 7.99 ± 4.17 |  | 39.99 ± 5.82 |  | 42.40 ± 8.01 |  |
| High school/technical secondary school | 84 (23.8) | 10.25 ± 2.88 |  | 41.42 ± 4.83 |  | 44.55 ± 6.98 |  |
| Junior college/bachelor’s degree and above | 177 (50.1) | 11.18 ± 2.75 |  | 42.47 ± 5.05 |  | 44.89 ± 7.29 |  |
| Work status |  |  | < 0.001 |  | 0.002 |  | 0.012 |
| Employed | 185 (52.4) | 10.79 ± 2.96 |  | 42.39 ± 4.90 |  | 45.13 ± 6.83 |  |
| Other | 168 (47.6) | 9.23 ± 3.78 |  | 40.68 ± 5.44 |  | 43.17 ± 7.85 |  |
| Monthly per capita income |  |  | < 0.001 |  | 0.003 |  | 0.074 |
| < 5000 | 173 (49.0) | 9.32 ± 3.87 |  | 40.61 ± 5.20 |  | 43.29 ± 7.95 |  |
| 5000-10000 | 104 (29.5) | 10.88 ± 2.52 |  | 42.37 ± 4.96 |  | 45.21 ± 6.59 |  |
| > 10000 | 76 (21.5) | 10.55 ± 3.27 |  | 42.68 ± 5.32 |  | 44.87 ± 6.93 |  |
| Marital status |  |  | 0.029 |  | 0.939 |  | 0.201 |
| Unmarried or other | 157 (44.5) | 10.50 ± 3.21 |  | 41.60 ± 5.25 |  | 44.76 ± 7.40 |  |
| Married | 196 (55.5) | 9.69 ± 3.62 |  | 41.56 ± 5.23 |  | 43.74 ± 7.37 |  |
| Smoking habit |  |  | 0.163 |  | 0.386 |  | 0.202 |
| No (no smoking) | 282 (79.9) | 10.18 ± 3.33 |  | 41.45 ± 5.13 |  | 43.94 ± 7.18 |  |
| Yes (smoking or used to smoke) | 71 (20.1) | 9.54 ± 3.92 |  | 42.06 ± 5.63 |  | 45.20 ± 8.14 |  |
| Drinking habit |  |  | 0.461 |  | 0.744 |  | 0.372 |
| No (no drinking) | 240 (68.0) | 10.14 ± 3.40 |  | 41.51 ± 5.27 |  | 43.95 ± 7.36 |  |
| Yes (drinking or used to drink) | 113 (32.0) | 9.85 ± 3.59 |  | 41.71 ± 5.16 |  | 44.71 ± 7.47 |  |
| Medical insurance type (multiple choices) |  |  |  |  |  |  |  |
| Basic medical insurance for urban employees | 187 (53.0) | 10.68 ± 3.06 | < 0.001 | 43.62 ± 4.98 | < 0.001 | 44.79 ± 7.14 | 0.108 |
| New cooperative medical insurance | 112 (31.7) | 9.16 ± 4.02 | 0.001 | 54.18 ± 5.45 | 0.001 | 43.34 ± 7.88 | 0.138 |
| Basic medical insurance for urban residents | 62 (17.6) | 9.18 ± 3.77 | 0.029 | 55.13 ± 4.87 | 0.460 | 44.56 ± 6.71 | 0.666 |
| Commercial insurance | 23 (6.5) | 10.74 ± 3.37 | 0.323 | 56.30 ± 4.76 | 0.490 | 45.61 ± 7.24 | 0.343 |
| No insurance | 3 (0.8) | 12.33 ± 1.15 | 0.252 | 52.00 ± 4.58 | 0.235 | 34.67 ± 9.29 | 0.025 |
| Which IBD |  |  | < 0.001 |  | 0.005 |  | 0.553 |
| Ulcerative colitis | 133 (37.7) | 9.16 ± 3.69 |  | 54.57 ± 5.06 |  | 43.89 ± 7.55 |  |
| Crohn’s disease | 220 (62.3) | 10.59 ± 3.21 |  | 56.18 ± 5.25 |  | 44.38 ± 7.30 |  |
| Duration of IBD |  |  | 0.995 |  | 0.948 |  | 0.248 |
| < 1 yr | 239 (67.7) | 10.05 ± 3.46 |  | 55.58 ± 5.17 |  | 44.65 ± 7.36 |  |
| 1-2 yr | 59 (16.7) | 10.08 ± 3.43 |  | 55.41 ± 5.30 |  | 43.17 ± 7.72 |  |
| > 2 yr | 55 (15.6) | 10.02 ± 3.56 |  | 55.73 ± 5.59 |  | 43.33 ± 7.09 |  |
| Ostomy |  |  | 0.014 |  | 0.088 |  | 0.621 |
| Yes | 27 (7.6) | 8.48 ± 4.37 |  | 53.93 ± 5.95 |  | 43.52 ± 10.05 |  |
| No | 326 (92.4) | 10.18 ± 3.53 |  | 55.71 ± 5.15 |  | 44.25 ± 7.14 |  |
| Comorbidities |  |  | 0.463 |  | 0.064 |  | 0.004 |
| Yes | 59 (16.7) | 9.75 ± 3.72 |  | 54.42 ± 5.11 |  | 41.71 ± 7.32 |  |
| No | 294 (83.3) | 10.11 ± 3.41 |  | 55.81 ± 5.23 |  | 44.64 ± 7.28 |  |
| Family history of IBD |  |  | 0.588 |  | 0.991 |  | 0.392 |
| Yes | 9 (2.5) | 10.67 ± 4.21 |  | 55.56 ± 4.98 |  | 42.11 ± 6.43 |  |
| No | 344 (97.5) | 10.03 ± 3.45 |  | 55.58 ± 5.24 |  | 44.25 ± 7.41 |  |
| Surgical history |  |  | 0.340 |  | 0.487 |  | 0.894 |
| Yes | 165 (46.7) | 10.24 ± 3.39 |  | 55.78 ± 5.10 |  | 44.14 ± 7.47 |  |
| No | 188 (53.3) | 9.88 ± 3.53 |  | 55.39 ± 5.35 |  | 44.24 ± 7.34 |  |
| History of drug allergy |  |  | 0.110 |  | 0.120 |  | 0.890 |
| Yes | 48 (13.6) | 10.79 ± 2.73 |  | 56.67 ± 5.15 |  | 44.33 ± 7.36 |  |
| No | 305 (86.4) | 9.93 ± 3.55 |  | 55.40 ± 5.23 |  | 44.17 ± 7.41 |  |
| What kind of treatment is being received? |  |  | 0.040 |  | 0.004 |  | 0.276 |
| 5-aminosalicylic acid drugs (*e.g.,* mesalazine) | 19 (5.4) | 8.63 ± 3.44 |  | 55.00 ± 4.99 |  | 45.32 ± 8.87 |  |
| Glucocorticoids | 1 (0.3) | 12.00 |  | 57.00 |  | 50.00 |  |
| Immunosuppressants (*e.g.,* azathioprine, tacrolimus, cyclosporine, *etc.*) | 6 (1.7) | 6.50 ± 3.27 |  | 51.33 ± 6.38 |  | 37.83 ± 9.99 |  |
| Biological agents (*e.g.,* infliximab, vedolizumab, ustekinumab) | 301 (85.3) | 10.16 ± 3.49 |  | 55.97 ± 5.13 |  | 44.33 ± 7.26 |  |
| Biological agents + immunosuppressants | 14 (4.0) | 9.93 ± 3.34 |  | 51.36 ± 5.58 |  | 43.57 ± 6.73 |  |
| Biological agents + 5-aminosalicylic acid drugs | 12 (3.4) | 11.25 ± 1.48 |  | 53.42 ± 4.36 |  | 42.50 ± 6.99 |  |

IBD: Inflammatory bowel disease.

**Table 2 Knowledge dimension, *n* (%)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Knowledge** | **Correct** | **Wrong** | **Unclear** |
| IBD is a group of chronic, non-specific recurrent intestinal inflammatory diseases, including UC and CD | 316 (89.5) | 2 (0.6) | 35 (9.9) |
| At present, many factors, such as heredity, immunity, environment, and microorganisms, are involved in the pathogenesis of the disease | 74 (21.0) | 185 (52.4) | 94 (26.6) |
| Symptoms of IBD can include abdominal pain, diarrhea, bloody stool, anemia, fever, joint swelling, pain, *etc.* | 293 (83.0) | 13 (3.7) | 47 (13.3) |
| Extraintestinal manifestations of IBD include oral ulcers, joint injury, skin injury, eye lesions, hepatobiliary diseases, *etc.* | 212 (60.1) | 32 (9.1) | 109 (30.9) |
| IBD often occurs in young adults and is more common between the ages of 20-50 yr | 267 (75.6) | 16 (4.5) | 70 (19.8) |
| IBD is a lifelong disease, and the patient’s condition is prolonged and repeated. At present, there is no specific and effective medicine or method to cure the disease | 293 (83.0) | 11 (3.1) | 49 (13.9) |
| Colonoscopy and mucosal biopsy are the best methods to establish the diagnosis and assess the disease’s severity in patients with IBD | 285 (80.7) | 6 (1.7) | 62 (17.6) |
| Generally, medical treatment is the main treatment for IBD, but surgical treatment is needed when intestinal obstruction, intestinal perforation, and canceration occur | 275 (77.9) | 5 (1.4) | 73 (20.7) |
| The treatment of patients with IBD varies widely among individuals, with different classifications and severity of the disease leading to different treatment outcomes and efficacy | 299 (84.7) | 1 (0.3) | 53 (15.0) |
| Drugs for treating IBD include hormones, aminosalicylic acid drugs, immunosuppressants (azathioprine, methotrexate, *etc.*), and biological agents | 274 (77.6) | 5 (1.4) | 74 (21.0) |
| There are no side effects after treatment with glucocorticoids, *etc.* | 149 (42.2) | 39 (11.0) | 165 (46.7) |
| Currently, the biological agents approved for treating IBD in China include infliximab, vidrizumab, and ustekinumab | 292 (82.7) | 6 (1.7) | 55 (15.6) |
| All patients with IBD can’t normally absorb the nutrients they intake | 232 (65.7) | 60 (17.0) | 61 (17.3) |
| Emotion, smoking, drinking, and other behaviors will not affect IBD | 286 (81.0) | 36 (10.2) | 31 (8.8) |

IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease.

**Table 3 Attitude dimension, *n* (%)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Attitude** | **Strongly agree** | **Agree** | **Neutral** | **Disagree** | **Strongly disagree** |
| I am confident in the treatment of IBD | 158 (44.8) | 134 (38.0) | 58 (16.4) | 3 (0.8) | 0 |
| I think patients with IBD need to avoid certain foods | 186 (52.7) | 144 (40.8) | 22 (6.2) | 1 (0.3) | 0 |
| I think that patients with IBD combined with malnutrition need to use a combination of intestinal and extra-intestinal nutrition support according to the disease situation if necessary | 171 (48.4) | 151 (42.8) | 29 (8.2) | 1 (0.3) | 1 (0.3) |
| I think scientific dietary guidance and management are key to managing IBD | 193 (54.7) | 141 (39.9) | 18 (5.1) | 1 (0.3) | 0 |
| I think developing a specific treatment plan for IBD needs to be tailored to the individual’s situation and developed jointly by the IBD medical specialist and the patient | 208 (58.9) | 129 (36.5) | 15 (4.2) | 1 (0.3) | 0 |
| I think the adjustment of IBD medication needs to be carried out under the guidance of specialists, and patients should not adjust their own medication | 228 (64.6) | 112 (31.7) | 13 (3.7) | 0 | 0 |
| I believe that during IBD medication, patients need to monitor the side effects of their medication and provide timely feedback to their specialists | 216 (61.2) | 128 (36.3) | 9 (2.5) | 0 | 0 |
| I think treatment can be stopped when the colonoscopy shows mucosal healing (*i.e.,* complete healing of colonic erosions and ulcers) | 37 (10.5) | 47 (13.3) | 92 (26.1) | 134 (38.0) | 43 (12.2) |
| I think the early application of biologics, in conjunction with specialist advice, will allow early control of disease activity to change the course of the disease and minimize complications and disability in the bowel | 171 (48.4) | 147 (41.6) | 30 (8.5) | 3 (0.8) | 2 (0.6) |
| I think patients with IBD should reduce their intake of saturated fatty acids (animal oil, cream, fatty meats, meat soups, *etc.*) | 137 (38.8) | 156 (44.2) | 52 (14.7) | 7 (2.0) | 1 (0.3) |
| I think that IBD patients should try to drink plain hot water and freshly squeezed juices and need to avoid strong tea, sugary drinks, coffee, alcohol, *etc.* | 177 (50.1) | 148 (41.9) | 24 (6.8) | 2 (0.6) | 2 (0.6) |
| I think the IBD disease has obviously increased the family’s financial burden | 172 (48.7) | 133 (37.7) | 42 (11.9) | 5 (1.4) | 1 (0.3) |
| I think I can get married, get pregnant, and give birth normally if my IBD disease is controlled | 125 (35.4) | 166 (47.0) | 52 (14.7) | 8 (2.3) | 2 (0.6) |
| I think IBD has affected my normal work, study, and social interaction | 98 (27.8) | 134 (38.0) | 86 (24.4) | 30 (8.5) | 5 (1.4) |

IBD: Inflammatory bowel disease.

**Table 4 Practice dimension, *n* (%)**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Practice** | **Always** | **Often** | **Sometimes** | | **Seldom** | **Never** |
| I will actively cooperate with the medical staff for my treatment and nursing | 244 (69.1) | 93 (26.3) | 15 (4.2) | | 1 (0.3) | 0 |
| I will communicate with specialists regularly and follow up regularly | 166 (47.0) | 116 (32.9) | 62 (17.6) | | 9 (2.5) | 0 |
| I will vent my bad emotions correctly, such as through exercise relaxation, music relaxation, and implied adjustment, to relieve mental stress | 106 (30.0) | 125 (35.4) | 92 (26.1) | | 25 (7.1) | 5 (1.4) |
| I will communicate with family members, close friends, and patients and gain encouragement and emotional support | 94 (26.6) | 117 (33.1) | 92 (26.1) | | 41 (11.6) | 9 (2.5) |
|  | Yes, *n* (%) | | | No, *n* (%) | | |
| I will take care to quit smoking and drinking | 346 (98.0) | | | 7 (2.0) | | |
| I will take care to avoid staying up late and overworking | 120 (34.0) | 119 (33.7) | 87 (24.6) | | 23 (6.5) | 4 (1.1) |
| I will take care to choose appropriate physical exercise according to my physical condition | 96 (27.2) | 95 (26.9) | 105 (29.7) | | 50 (14.2) | 7 (2.0) |
| If there is an ostomy, I will go to an IBD specialist for standard treatment | 336 (95.2) | 17 (4.8) | 0 | | 0 | 0 |
| If I am treated with biological agents, I will pay attention to monitoring the related side effects | 179 (50.7) | 107 (30.3) | 52 (14.7) | | 11 (3.1) | 4 (1.1) |
| If a food allergy is identified, I will take care to avoid it in my daily diet | 210 (59.5) | 105 (29.7) | 30 (8.5) | | 5 (1.4) | 3 (0.8) |
| I will use a “diet diary” to identify foods that may cause discomfort, such as abdominal pain or diarrhea, and try to avoid them in my future diet | 106 (30.0) | 94 (26.6) | 67 (19.0) | | 42 (11.9) | 44 (12.5) |
| I will improve my understanding of diseases and treatment through WeChat groups, networks, and popular science lectures | 100 (28.3) | 85 (24.1) | 104 (29.5) | | 52 (14.7) | 12 (3.4) |
| I will insist on taking medicine or receiving infusion treatment of biological agents as prescribed by my physician | 247 (70.0) | 86 (24.4) | 16 (4.5) | | 3 (0.8) | 1 (0.3) |
| I will encourage and help other people with IBD as much as I can | 135 (38.2) | 78 (22.1) | 93 (26.3) | | 37 (10.5) | 10 (2.8) |

IBD: Inflammatory bowel disease.

**Table 5 Correlation analysis**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Knowledge dimension** | **Attitude** | **Practice** |
| Knowledge dimension | 1 |  |  |
| Attitude | 0.371 (*P* < 0.001) | 1 |  |
| Practice | 0.100 (*P* < 0.001) | 0.452 (*P* < 0.001) | 1 |

**Table 6 Univariate and multivariate analysis of knowledge**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Univariate analysis** | | **Multivariate analysis** | |
| **OR (95%CI)** | ***P* value** | **OR (95%CI)** | ***P* value** |
| Gender |  |  |  |  |
| Male | 1.09 (0.62-1.92) | 0.751 |  |  |
| Female | Ref |  |  |  |
| Age |  |  |  |  |
| ≤ 20 | Ref |  | Ref |  |
| 20-30 | 2.80 (1.10-7.09) | 0.030 | 3.01 (0.97-9.38) | 0.057 |
| 30-40 | 2.17 (0.84-5.63) | 0.111 | 4.06 (1.04-15.82) | 0.043 |
| > 40 | 0.76 (0.33-1.75) |  |  |  |
| Ethnicity |  |  |  |  |
| Han | 3.83 (1.13-12.94) | 0.031 | 3.70 (0.80-16.97) | 0.093 |
| Minorities | Ref |  | Ref |  |
| Residence |  |  |  |  |
| Rural | Ref |  | Ref |  |
| City | 3.08 (1.56-6.07) | 0.001 | 1.69 (0.74-3.84) | 0.213 |
| Suburb/urban-rural combination | 1.95 (0.97-3.90) | 0.060 | 1.33 (0.58-3.03) | 0.496 |
| Education |  |  |  |  |
| Primary school and below | Ref |  |  |  |
| Middle school | 2.99 (1.15-7.76) | 0.025 | 3.98 (1.29-12.33) | 0.017 |
| High school/technical secondary school | 11.80 (4.20-33.17) | < 0.001 | 14.06 (3.92-50.38) | < 0.001 |
| Junior college/bachelor’s degree and above | 20.70 (7.75-55.28) | < 0.001 | 15.20 (4.15-55.65) | < 0.001 |
| Work status |  |  |  |  |
| Employed | 4.07 (2.23-7.41) | < 0.001 | 1.34 (0.63-2.85) | 0.444 |
| Other | Ref |  | Ref |  |
| Monthly per capita income |  |  |  |  |
| < 5000 | Ref |  | Ref |  |
| 5000-10000 | 3.94 (1.84-8.43) | < 0.001 | 2.04 (0.81-5.18) | 0.133 |
| > 10000 | 2.46 (1.17-5.18) | 0.018 | 0.90 (0.34-2.36) | 0.823 |
| Marital status |  |  |  |  |
| Unmarried or other | Ref |  | Ref |  |
| Married | 0.61 (0.35-1.07) | 0.083 | 0.85 (0.33-2.16) | 0.734 |
| Smoking habit |  |  |  |  |
| No (no smoking) | Ref |  |  |  |
| Yes (smoking or used to smoke) | 0.60 (0.33-1.12) | 0.10 |  |  |
| Drinking habit |  |  |  |  |
| No (no drinking) | Ref |  |  |  |
| Yes (drinking or used to drink) | 0.85 (0.49-1.50) | 0.584 |  |  |
| What kind of IBD is being diagnosed |  |  |  |  |
| Ulcerative colitis | 0.50 (0.29-0.85) | 0.011 | 0.57 (0.28-1.18) | 0.132 |
| Crohn’s disease | Ref |  | Ref |  |
| Duration of IBD |  |  |  |  |
| < 1 yr | 1.14 (0.54-2.39) | 0.729 |  |  |
| 1-2 yr | 0.98 (0.39-2.45) | 0.964 |  |  |
| > 2 yr | Ref |  |  |  |
| Ostomy? |  |  |  |  |
| Yes | 0.51 (0.21-1.23) | 0.135 |  |  |
| No | Ref |  |  |  |
| Comorbidities |  |  |  |  |
| Yes | 0.62 (0.32-1.19) | 0.149 |  |  |
| None | Ref |  |  |  |
| Family history of IBD |  |  |  |  |
| Yes | 1.86 (0.23-15.16) | 0.560 |  |  |
| No | Ref |  |  |  |
| Surgical history |  |  |  |  |
| Yes | 1.15 (0.67-1.97) | 0.613 |  |  |
| No | Ref |  |  |  |
| History of drug allergy |  |  |  |  |
| Yes | 1.40 (0.60-3.29) | 0.433 |  |  |
| No | Ref |  |  |  |
| What kind of treatment is being received? |  |  |  |  |
| 5-aminosalicylic acid drugs (*e.g.,* mesalazine) | Ref |  |  |  |
| Glucocorticoids | - | - |  |  |
| Immunosuppressants (*e.g.,* azathioprine, tacrolimus, cyclosporine, *etc.*) | 0.46 (0.07-2.99) | 0.418 |  |  |
| Biological agents (*e.g.,* infliximab, vedolizumab, ustekinumab) | 2.11 (0.77-5.80) | 0.148 |  |  |
| Biological agents + immunosuppressants | 1.69 (0.34-8.40) | 0.520 |  |  |
| Biological agents + 5-aminosalicylic acid drugs | - | - |  |  |

IBD: Inflammatory bowel disease.

**Table 7 Univariate and multivariate analysis of attitude**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Univariate analysis** | | **Multivariate analysis** | |
| **OR (95%CI)** | ***P* value** | **OR (95%CI)** | ***P* value** |
| **Knowledge score (as continuous variables)** | 1.24 (1.14-1.34) | < 0.001 | 1.23 (1.11 1.36) | < 0.001 |
| Gender |  |  |  |  |
| Male | 1.42 (0.73-2.74) | 0.300 |  |  |
| Female | Ref |  |  |  |
| Age |  |  |  |  |
| ≤ 20 | Ref |  |  |  |
| 20-30 | 1.49 (0.52-4.25) | 0.461 |  |  |
| 30-40 | 1.29 (0.43-3.82) | 0.651 |  |  |
| > 40 | 1.27 (0.44-3.65) | 0.656 |  |  |
| Ethnicity |  |  |  |  |
| Han | 4.69 (1.31-16.80) | 0.017 | 3.21 (0.66 15.59) | 0.149 |
| Minorities | Ref |  | Ref |  |
| Residence |  |  |  |  |
| Rural | Ref |  | Ref |  |
| City | 2.47 (1.06-5.76) | 0.037 | 1.63 (0.61 4.32) | 0.329 |
| Suburb/urban-rural combination | 1.12 (0.51-2.44) | 0.779 | 0.98 (0.39 2.47) | 0.968 |
| Education |  |  |  |  |
| Primary school and below | Ref |  | Ref |  |
| Middle school | 0.95 (0.30-2.97) | 0.925 | 0.85 (0.23 3.08) | 0.803 |
| High school/technical secondary school | 2.37 (0.70-8.05) | 0.165 | 0.87 (0.22 3.49) | 0.841 |
| Junior college/bachelor’s degree and above | 2.91 (0.95-8.94) | 0.062 | 0.82 (0.20 3.26) | 0.774 |
| Work status |  |  |  |  |
| Employed | 2.65 (1.32-5.30) | 0.006 | 1.54 (0.64 3.70) | 0.338 |
| Other | Ref |  | Ref |  |
| Monthly per capita income |  |  |  |  |
| < 5000 | Ref |  | Ref |  |
| 5000-10000 | 2.22 (0.97-5.09) | 0.060 | 1.10 (0.42 2.89) | 0.850 |
| > 10000 | 2.16 (0.85-5.46) | 0.105 | 1.06 (0.35 3.17) | 0.924 |
| Marital status |  |  |  |  |
| Unmarried or other | Ref |  |  |  |
| Married | 0.97 (0.51-1.88) | 0.937 |  |  |
| Smoking habit |  |  |  |  |
| No (no smoking) | Ref |  |  |  |
| Yes (smoking or used to smoke) | 0.88 (0.40-1.94) | 0.755 |  |  |
| Drinking habit |  |  |  |  |
| No (no drinking) | Ref |  |  |  |
| Yes (drinking or used to drink) | 1.16 (0.57-2.36) | 0.689 |  |  |
| What kind of IBD is being diagnosed |  |  |  |  |
| Ulcerative colitis | 0.75 (0.39-1.44) | 0.383 |  |  |
| Crohn’s disease | Ref |  |  |  |
| Duration of IBD |  |  |  |  |
| < 1 yr | 0.92 (0.36-2.35) | 0.866 |  |  |
| 1-2 yr | 0.91 (0.29-2.90) | 0.873 |  |  |
| > 2 yr | Ref |  |  |  |
| Ostomy? |  |  |  |  |
| Yes | 0.55 (0.19-1.53) | 0.250 |  |  |
| No | Ref |  |  |  |
| Comorbidities |  |  |  |  |
| Yes | 0.68 (0.31-1.51) | 0.341 |  |  |
| None | Ref |  |  |  |
| Family history of IBD |  |  |  |  |
| Yes | 1.05 (0.13-8.64) | 0.962 |  |  |
| No | Ref |  |  |  |
| Surgical history |  |  |  |  |
| Yes | 1.14 (0.59-2.19) | 0.698 |  |  |
| No | Ref |  |  |  |
| History of drug allergy |  |  |  |  |
| Yes | 1.52 (0.52-4.47) | 0.448 |  |  |
| No | Ref |  |  |  |
| What kind of treatment is being received? |  |  |  |  |
| 5-aminosalicylic acid drugs (*e.g.,* mesalazine) | Ref |  | Ref |  |
| Glucocorticoids | - | - | - | - |
| Immunosuppressants (*e.g.,* azathioprine, tacrolimus, cyclosporine, *etc.*) | 0.24 (0.02-2.22) | 0.206 | 0.38 (0.03-4.43) | 0.438 |
| Biological agents (*e.g.,* infliximab, vedolizumab, ustekinumab) | 1.10 (0.24-5.02) | 0.899 | 0.88 (0.17-4.53) | 0.878 |
| Biological agents + immunosuppressants | 0.21 (0.03-1.32) | 0.096 | 0.16 (0.02-1.17) | 0.070 |
| Biological agents + 5-aminosalicylic acid drugs | 0.35 (0.05-2.51) | 0.298 | 0.17 (0.02-1.51) | 0.113 |

IBD: Inflammatory bowel disease.

**Table 8 Univariate and multivariate analysis of practice**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Univariate analysis** | | **Multivariate analysis** | |
| **OR (95%CI)** | ***P* value** | **OR (95%CI)** | ***P* value** |
| Knowledge score (as continuous variables) | 1.10 (1.02-1.19) | 0.020 | 0.96 (0.87-1.06) | 0.412 |
| Attitude score (as continuous variables) | 1.21 (1.13-1.30) | < 0.001 | 1.20 (1.11-1.30) | < 0.001 |
| Gender |  |  |  |  |
| Male | 1.62 (0.86-3.04) | 0.134 |  |  |
| Female | Ref |  |  |  |
| Age |  |  |  |  |
| ≤ 20 | Ref |  |  |  |
| 20-30 | 1.25 (0.45-3.50) | 0.672 |  |  |
| 30-40 | 1.65 (0.53-5.11) | 0.386 |  |  |
| > 40 | 1.16 (0.41-3.30) | 0.780 |  |  |
| Ethnicity |  |  |  |  |
| Han | 0.65 (0.14-3.11) | 0.589 |  |  |
| Minorities | Ref |  |  |  |
| Residence |  |  |  |  |
| Rural | Ref |  | Ref |  |
| City | 2.41 (1.08-5.40) | 0.033 | 2.01 (0.80-5.04) | 0.139 |
| Suburb/urban-rural combination | 1.12 (0.53-2.38) | 0.768 | 1.12 (0.49-2.58) | 0.788 |
| Education |  |  |  |  |
| Primary school and below | Ref |  |  |  |
| Middle school | 0.66 (0.20-2.22) | 0.503 |  |  |
| High school/technical secondary school | 2.10 (0.56-7.84) | 0.272 |  |  |
| Junior college/bachelor’s degree and above | 1.58 (0.49-5.11) | 0.441 |  |  |
| Work status |  |  |  |  |
| Employed | 2.76 (1.41-5.40) | 0.003 | 1.93 (0.88-4.21) | 0.099 |
| Other | Ref |  | Ref |  |
| Monthly per capita income |  |  |  |  |
| < 5000 | Ref |  | Ref |  |
| 5000-10000 | 2.42 (1.06-5.51) | 0.036 | 1.31 (0.51-3.33) | 0.578 |
| > 10000 | 1.71 (0.74-3.94) | 0.207 | 0.86 (0.32-2.28) | 0.755 |
| Marital status |  |  |  |  |
| Unmarried or other | Ref |  |  |  |
| Married | 0.65 (0.34-1.25) | 0.200 |  |  |
| Smoking habit |  |  |  |  |
| No (no smoking) | Ref |  |  |  |
| Yes (smoking or used to smoke) | 0.86 (0.41-1.84) | 0.706 |  |  |
| Drinking habit |  |  |  |  |
| No (no drinking) | Ref |  |  |  |
| Yes (drinking or used to drink) | 1.18 (0.60-2.35) | 0.631 |  |  |
| What kind of IBD is being diagnosed |  |  |  |  |
| Ulcerative colitis | 0.80 (0.43-1.52) | 0.501 |  |  |
| Crohn’s disease | Ref |  |  |  |
| Duration of IBD |  |  |  |  |
| < 1 yr | 1.39 (0.59-3.27) | 0.445 |  |  |
| 1-2 yr | 0.74 (0.27-2.01) | 0.558 |  |  |
| > 2 yr | Ref |  |  |  |
| Ostomy |  |  |  |  |
| Yes | 0.62 (0.22-1.72) | 0.354 |  |  |
| No | Ref |  |  |  |
| Comorbidities |  |  |  |  |
| Yes | 0.43 (0.21-0.88) | 0.022 | 0.50 (0.23-1.09) | 0.082 |
| None | Ref |  | Ref |  |
| Family history of IBD |  |  |  |  |
| Yes | - | - |  |  |
| No | Ref |  |  |  |
| Surgical history |  |  |  |  |
| Yes | 1.11 (0.59-2.09) | 0.741 |  |  |
| No | Ref |  |  |  |
| History of drug allergy |  |  |  |  |
| Yes | 0.83 (0.35-1.99) | 0.682 |  |  |
| No | Ref |  |  |  |
| What kind of treatment is being received? |  |  |  |  |
| 5-aminosalicylic acid drugs (*e.g.,* mesalazine) | Ref |  |  |  |
| Glucocorticoids | - | - |  |  |
| Immunosuppressants (*e.g.,* azathioprine, tacrolimus, cyclosporine, *etc.*) | 0.19 (0.02-1.41) | 0.104 |  |  |
| Biological agents (*e.g.,* infliximab, vedolizumab, ustekinumab) | 1.38 (0.38-4.97) | 0.622 |  |  |
| Biological agents + immunosuppressants | 2.44 (0.23-26.30) | 0.463 |  |  |
| Biological agents + 5-aminosalicylic acid drugs | 0.94 (0.13-6.63) | 0.948 |  |  |

IBD: Inflammatory bowel disease.